Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

2.

Burger

JA

.

Treatment of chronic lymphocytic leukemia

.

N Engl J Med

.

2020

;

383

(

5

):

460

-

473

.

3.

Burger

JA

,

Barr

PM

,

Robak

T

, et al.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

.

Leukemia

.

2020

;

34

(

3

):

787

-

798

.

4.

Hamblin

TJ

,

Davis

Z

,

Gardiner

A

,

Oscier

DG

,

Stevenson

FK

.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia

.

Blood

.

1999

;

94

(

6

):

1848

-

1854

.

5.

Damle

RN

,

Wasil

T

,

Fais

F

, et al.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

.

Blood

.

1999

;

94

(

6

):

1840

-

1847

.

6.

Packham

G

,

Krysov

S

,

Allen

A

, et al.

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy

.

Haematologica

.

2014

;

99

(

7

):

1138

-

1148

.

7.

D'Avola

A

,

Drennan

S

,

Tracy

I

, et al.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL

.

Blood

.

2016

;

128

(

6

):

816

-

826

.

8.

Burger

JA

,

Wiestner

A

.

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

.

Nat Rev Cancer

.

2018

;

18

(

3

):

148

-

167

.

9.

Ten Hacken

E

,

Sivina

M

,

Kim

E

, et al.

Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia

.

J Immunol

.

2016

;

197

(

6

):

2522

-

2531

.

10.

Rassenti

LZ

,

Huynh

L

,

Toy

TL

, et al.

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

.

N Engl J Med

.

2004

;

351

(

9

):

893

-

901

.

11.

Chen

J

,

Sathiaseelan

V

,

Reddy Chilamakuri

CS

, et al.

ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia

.

Blood Adv

.

2024

;

8

(

5

):

1167

-

1178

.

12.

Chen

L

,

Huynh

L

,

Apgar

J

, et al.

ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia

.

Blood

.

2008

;

111

(

5

):

2685

-

2692

.

13.

Rawstron

AC

,

Villamor

N

,

Ritgen

M

, et al.

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

.

Leukemia

.

2007

;

21

(

5

):

956

-

964

.

14.

Admirand

JH

,

Rassidakis

GZ

,

Abruzzo

LV

,

Valbuena

JR

,

Jones

D

,

Medeiros

LJ

.

Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma

.

Mod Pathol

.

2004

;

17

(

8

):

954

-

961

.

15.

Messmer

BT

,

Messmer

D

,

Allen

SL

, et al.

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

.

J Clin Invest

.

2005

;

115

(

3

):

755

-

764

.

16.

Wodarz

D

,

Garg

N

,

Komarova

NL

, et al.

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

.

Blood

.

2014

;

123

(

26

):

4132

-

4135

.

17.

Murphy

EJ

,

Neuberg

DS

,

Rassenti

LZ

, et al.

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

.

Leukemia

.

2017

;

31

(

6

):

1348

-

1354

.

18.

Woyach

JA

,

Smucker

K

,

Smith

LL

, et al.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

.

Blood

.

2014

;

123

(

12

):

1810

-

1817

.

19.

Sharman

JP

,

Egyed

M

,

Jurczak

W

, et al.

Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

636

.

20.

Thompson

PA

,

Tam

CS

,

O'Brien

SM

, et al.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

.

Blood

.

2016

;

127

(

3

):

303

-

309

.

21.

Al-Sawaf

O

,

Zhang

C

,

Tandon

M

, et al.

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2020

;

21

(

9

):

1188

-

1200

.

22.

Tam

CS

,

Allan

JN

,

Siddiqi

T

, et al.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

.

Blood

.

2022

;

139

(

22

):

3278

-

3289

.

23.

Niemann

CU

,

Munir

T

,

Moreno

C

, et al.

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2023

;

24

(

12

):

1423

-

1433

.

24.

Munir

T

,

Cairns

DA

,

Bloor

A

, et al.

Chronic lymphocytic leukemia therapy guided by measurable residual disease

.

N Engl J Med

.

2024

;

390

(

4

):

326

-

337

.